3-Year Clinical Data Continue to Show Superiority of Sirolimus-Eluting versus Bare Metal Stents in STEMI Patients

Summary

Results of 3 years of clinical follow-up data continued to show superiority for a combination of tirofiban+sirolimus-eluting stent (SES) vs a combination of abciximab+bare-metal stent (BMS) in STEMI patients, as evidenced by significantly reduced target vessel revascularization (TVR) rates.

  • cardiology clinical trials
  • myocardial infarction
  • interventional techniques & devices
View Full Text
Back to top

Tools

View Full Page PDF
Citation Tools
Email
3-Year Clinical Data Continue to Show Superiority of Sirolimus-Eluting versus Bare Metal Stents in STEMI Patients
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Cardiology Clinical Trials
Myocardial Infarction
Interventional Techniques & Devices